Latest News for: androstenedione

Edit

Neurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst™ Pediatric Study Demonstrating CRENESSITY™ Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups

PR Newswire 08 May 2025
- Data Consistent Across All Patient Subgroups, Including Demographic Subgroups, by Baseline Androstenedione Levels and by Baseline Glucocorticoid Dose ... For decades, high levels of androstenedione (A4) were treated with glucocorticoids (GCs) only.
  • 1

Article Search

tools
×
×
×
×